|Videos|April 3, 2017

Reducing Respiratory Viral HAIs in Pediatric Healthcare Settings

Matt Linam, MD, MS, Assistant Professor, Pediatric Infectious Diseases, University of Arkansas for Medical Sciences, explains the best ways to reduce the number of respiratory viral healthcare-associated infections in children.

Matt Linam, MD, MS, Assistant Professor, Pediatric Infectious Diseases, University of Arkansas for Medical Sciences, explains the best ways to reduce the number of respiratory viral healthcare-associated infections in children.

Interview Transcript (slightly modified for readability)

“The best plan of action for reducing respiratory viral healthcare-associated infections in children is really just focusing on the basics, things like hand hygiene, making sure healthcare workers are vaccinated, making sure that healthcare workers don’t come to work when they’re ill, are just some of the basic strategies that we do to prevent all kinds of healthcare-associated infections, but they seem to be very important for viral infections as well. But one area that we don’t often focus as much for other infections like bloodstream infections, and things like that, is the role that families and visitors can play in transmitting these infections.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.